OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. O'Neil Discusses the Development of Biomarkers for CRC

August 11th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

Dr. Erba on the FDA Approval of CPX-351 in AML

August 11th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL

August 11th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Dr. Lenz on Need for New Treatment Strategies in Colorectal Cancer

August 11th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the need for new treatment strategies in colorectal cancer.

The Clinical Value of MRI Testing in Prostate Cancer

August 11th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.

Dr. Hammers on the Future of Treatments for RCC

August 11th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer

August 11th 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

August 10th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Dr. Chase on Future Treatment Landscape of Gynecologic Malignancies

August 10th 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.

Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

August 10th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Dr. Kuerer on Margins of DCIS

August 10th 2017

Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).

Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

August 10th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Stephenson on Advancements of Treatment for Prostate Cancer

August 10th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses advancements being made in the field of prostate cancer.

Dr. Kaouk on Challenges Facing Surgery for RCC

August 10th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses challenges regarding robotic surgery for patients with renal cell carcinoma (RCC).

Dr. Weiss on Developments in the Treatment of Head and Neck Cancer

August 10th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

Dr. Schmoll on the Objective of CHARTA for CRC

August 10th 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

Dr. Arend Discusses MSI Testing in Gynecologic Malignancies

August 10th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.

Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

August 10th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.

Dr. Byrd on Updated RESONATE Findings in CLL

August 10th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of Medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the updated findings of the RESONATE trial in chronic lymphocytic leukemia (CLL).

Dr. Hamlin on Toxicities Associated With Ibrutinib and Buparlisib in MCL, FL, and DLBCL

August 10th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).